Nykredit A/S’s CG Oncology CGON Stock Holding History

Nykredit A/S’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Buy	+3,451	New	+$226K	﹤0.01%	951

Other funds holding CGON

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Nykredit A/S's CGON Position: Q2 2026 in Review

Nykredit A/S opened a new position in CG Oncology (CGON) in Q2 2026: 3,451 shares worth $245K. The stake represents ﹤0.01% of the portfolio and ranks #951 among its holdings.

151 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Nykredit A/S held 3,451 shares of CG Oncology worth $245K as of Q2 2026.
CG Oncology was a new Nykredit A/S position in Q2 2026.
CG Oncology made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #951 holding.
151 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.